US: CKDXF - Opthea Ltd

Yield per half year: -22.81%
Dividend yield: 0.00%

Share chart Opthea Ltd

Extended chart Simple chart
Financial Markets by TradingView

About Opthea Ltd

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

more details
The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://opthea.com
Цена ао 0.44
Change price per day: 0% (0.44)
Change price per week: 0% (0.44)
Change price per month: 0% (0.44)
Change price per 3 month: 0% (0.44)
Change price per half year: -22.81% (0.57)
Change price per year: +51.72% (0.29)
Change price per 3 year: -59.63% (1.09)
Change price per 5 year: -81.89% (2.43)
Change price per year to date: 0% (0.44)
All parameters

Underestimation

Title Value Grade
P/S 1484.6 1
P/BV -2.44 0
P/E 0 0
EV/EBITDA -0.774 0
Total: 2.75

Efficiency

Title Value Grade
ROA, % -130.72 0
ROE, % 520.65 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0.59

Debt

Title Value Grade
Debt/EBITDA -0.7108 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 107.95 10
Yield Ebitda, % 1044.01 10
Yield EPS, % 738.93 10
Total: 10
More

Head Job title Payment Year of birth
Dr. Frederic Guerard M.S., Pharm.D. Chief Executive Officer 1972 (53 years)
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. Founder, Chief Innovation Officer & Executive Director 1975 (50 years)
Ms. Karen Adams CPA VP of Finance & Company Secretary 1971 (54 years)
Mr. Daniel E. Geffken M.B.A. Interim CFO 1957 (68 years)
Mr. Kevin Bitter VP of Strategy & Corporate Development 1992 (33 years)
Ms. Sarika Gulhar Ph.D. Executive Director of Human Resources
Dr. Michael Gerometta Ph.D. Head of Chemistry, Manufacturing & Controls Development 1965 (60 years)
Dr. Kenneth Sall Chief Medical Officer
Dr. Fang Li Ph.D. Senior Vice President of Regulatory Affairs 1964 (61 year)
Dr. Julie Clark M.D., M.S. Senior Vice President of Clinical Development 1975 (50 years)

Address: Australia, South Yarra, 650 Chapel Street - open in Google maps, open in Yandex maps
Website: https://opthea.com